2026-01-22 - Analysis Report
**Company Overview**
Johnson & Johnson is a multinational healthcare company that develops and manufactures medical devices, consumer packaged goods, and pharmaceuticals.

**Comparison of Return Rates**

* Review stock (JNJ): Cumulative return = 60.16%
* Comparison stock (VOO, S&P 500): Cumulative return = 91.55%
* Divergence (max: 13.70, min: -62.40, current: -32.70, relative divergence: 39.00%)

The cumulative return of JNJ is significantly lower than the S&P 500, indicating a divergence of -31.39% from the comparison stock.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 6.0% | 16.8% | 2.0% | 0.7 | 310.9B |
| 2017-2019  | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020  | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021  | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022  | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023  | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024  | -30.0% | 13.8% | -49.0% | 0.2 | 348.4B |
| 2023-2025  | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

JNJ has had varying returns across different time periods. The most recent period (2023-2025) shows a significant increase in the cumulative return.

**Recent Stock Price Fluctuations**

* Close: $218.01
* Last-market price: $218.01 (change: -0.09)
* 5-day SMA: $218.60
* 20-day SMA: $210.02
* 60-day SMA: $202.80

The 5-day moving average is slightly higher than the current price, while the 20-day and 60-day moving averages are lower. This indicates a short-term uptrend and a potential reversal in the medium-term.

**RSI, PPO Index Indicators**

* Market Risk Indicator (MRI): 0.80
* RSI: 70.94
* PPO: 0.46
* Hybrid Signal: Buy
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: +14.60 (improving)
* 7-day Rank change: +30 (rank up)
* 7-day Dynamic Expected Return change: -1.30 (worsening)
* Expected Return (%): -38.60%

The Market Risk Indicator is at a medium level, indicating a relatively stable market. The RSI is above 70, indicating some overbought conditions. The PPO is below 1, indicating a sell signal. However, the hybrid signal suggests a buy.

**Recent News & Significant Events (Yahoo Finance)**

* How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily
* J&J stock drops after Q4 2025 results (JNJ:NYSE) - Seeking Alpha
* JNJ Earnings: Johnson & Johnson Stock Falls Despite Q4 Revenue Beat - TipRanks
* J&J's 2026 guidance driven by 'exciting' new product story - Yahoo Finance
* Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. - Barron's
* Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Hereâ€™s How to Buy Without the Risk - TipRanks

These news articles suggest that JNJ's Q4 results and guidance have been positive, but the stock has been falling due to market conditions and rival companies' performance.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 212.00 / 240.00 / 155.00

Analysts have a buy recommendation for JNJ with an average target price of $212.00.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

JNJ's earnings have been generally stable with some fluctuations between quarters. The recent quarter (2025-10-22) showed a higher EPS but lower revenue.

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

JNJ's revenue has been stable across different quarters, with some fluctuations in profit margins.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

JNJ's equity has been increasing, and ROE has been stable with some fluctuations across different quarters.

**Comprehensive Analysis (Summary of previous items)**

JNJ's performance has been mixed in the recent period. The stock price has been fluctuating, and the market risk indicator suggests a relatively stable market. Analysts have a buy recommendation for the stock with an average target price of $212.00. The company's revenue and profit margins have been stable across different quarters, but equity and ROE have shown some fluctuations. Overall, JNJ's performance is stable, but with some potential risks and opportunities.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.